AC
TMBR

Armistice Capital’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Armistice Capital’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-231
Closed -$382K – 82
2017
Q4 		$382K Buy
+231
New +$630K 0.04% 67

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.28B AUM 14.87% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Armistice Capital's TMBR Position: Q1 2018 in Review

Armistice Capital sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q1 2018, closing a stake of 231 shares — an estimated $382K sold.

Armistice Capital first reported a position in TMBR in Q4 2017 and held it in 1 quarter. The position peaked at $382K in Q4 2017. 21 funds tracked by Wall St. Rank hold TMBR as of Q1 2018.

  • Armistice Capital reported no remaining Timber Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Armistice Capital sold 231 Timber Pharmaceuticals, Inc. shares in Q1 2018, an estimated $382K.
  • Armistice Capital first reported a position in Timber Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Armistice Capital's Timber Pharmaceuticals, Inc. position peaked at $382K in Q4 2017.
  • 21 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q1 2018.

Based on Armistice Capital's 13F filing for Q1 2018, filed 15 May 2018.